Evidence map›Paper›PMID 40890660›Full record

ArticleBMC public health2025

Critical discourse analysis of social media advertisements for GLP-1 receptor agonist weight loss drugs: implications for public perceptions and health communication.

J Rad, G J Melendez-Torres

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Seeing Beyond GLP-1: A Systems View of Sustainable Obesity Care.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

J RadFaculty of Health and Life Sciences, University of Exeter, Exeter, UK. js1605@exeter.ac.uk.
G J Melendez-TorresFaculty of Health and Life Sciences, University of Exeter, Exeter, UK. g.j.melendez-torres@exeter.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study conducts a critical discourse analysis (CDA) of social media advertisements (ads) for Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) weight loss drugs to examine their linguistic features, discursive practices, and social implications, aiming to explore how advertising strategies may shape public perceptions and consumer considerations. Data collection focused on Facebook and Instagram, targeting ads related to FDA-approved GLP-1 RAs weight loss drugs from February 2023 to February 2024. Ads were collected using specific keyword searches. Inclusion criteria focused on ads explicitly related to the three GLP-1 RAs weight loss drugs, while exclusion criteria removed irrelevant, non-English, duplicate, or incomprehensible ads. Thematic analysis was conducted to identify recurring themes. Fairclough's CDA model was used to analyse the 90 ads. Thematic analysis identified four key themes including "Health and Safety", "Consultation and Support", "Ease and Affordability", and "Emotional and Psychological Impact". These themes highlight the emphasis on medical credibility, accessibility through telehealth, affordability, and emotional benefits. The ads strategically use medical authority and emotional appeals, seemingly to build trust and persuade consumers. The focus on telehealth aligns with the growing demand for remote healthcare solutions, while the emphasis on affordability and ease of use addresses common barriers to accessing weight loss treatments. This research provides new insights into the discursive strategies of pharmaceutical advertising, distinguishing it as a unique contribution to the field. The study underlines the need for balanced health communication that accurately represents the benefits and risks of weight loss drugs. It recommends stricter regulatory guidelines to ensure transparency and prevent exaggerated claims. Additionally, public health campaigns should educate consumers on comprehensive weight management, integrating medication with lifestyle changes. Moreover, stakeholders can develop better health communication strategies and regulatory policies to enhance public health outcomes by understanding the narratives in these ads.

Indexed as

AdvertisingAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsHealth CommunicationPublic OpinionSocial MediaHumansAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsCritical discourse analysisGLP-1 receptor agonistHealth communicationSocial media advertisingTelehealthWeight loss drugs

Identifiers

PMID40890660
PMCPMC12400570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.